Latest news with #ATEC
Yahoo
6 days ago
- Business
- Yahoo
Buy Now or Regret Later: This Small-Cap Stock Has Big Disruption Potential
Small-cap stocks rarely receive the attention they deserve in the massive medical technology (medtech) industry, which is dominated by bigger names like Intuitive Surgical (ISRG), Medtronic (MDT), Johnson & Johnson (JNJ), and Stryker (SYK). Valued at $1.5 billion, Alphatec Holdings (ATEC), a spinal-surgery-focused medtech firm, is one such under-the-radar name that is steadily attracting Wall Street and investor attention. Its products are specifically designed to simplify complex procedures, improve reproducibility, and help surgeons treat spinal conditions more effectively. More News from Barchart Opendoor Stock Is Surging Higher in a Frenzied Retail Rally. How Should You Play OPEN Shares Here? This Penny Stock Wants to Become the MicroStrategy of Dogecoin Robinhood Stock Stumbles as S&P 500 Inclusion Is Once Again Off the Table for HOOD Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Alphatec stock has gained 13% year-to-date, compared to the S&P 500 Index's ($SPX) gain of 7.7%. Let's dig in to determine why Alphatec stock is a smart buy now. Alphatec Is Setting the Stage for More Growth Alphatec is known for using artificial intelligence (AI) to create advanced, integrated surgical systems that include implants, imaging, navigation, robotics, and biologics. The company's goal is to revolutionize spinal surgery, making it safer and more effective for patients. Some of its innovative approaches include the Anterior/Posterior Cervical Discectomy & Fusion (ACDF/PCF), Lateral, Transforaminal, Anterior Lumbar Interbody Fusion (LTP/TLIF/ALIF), corpectomy systems, and PTP (Prone TransPsoas). While ATEC is still a small-cap firm, its revenue growth, product adoption, and expanding footprint point to a company writing a strong growth story. In the first quarter, total revenue increased 22% year-over-year to $169 million, along with 24% growth in surgical revenue. The company has developed a loyal base of highly engaged surgeons, and more trained surgeons are adopting ATEC systems. Q2 saw an 18% increase in new surgeon adoption, which is a positive indicator for future growth. Alphatec is aggressively investing in R&D and surgeon training, affecting short-term profits while increasing long-term value creation. R&D expenses totaled $16.6 million in the first quarter, resulting in a net loss of $51.9 million, or $0.35 per share. However, adjusted gross margin stood at an impressive 70% for the quarter. Alphatec ended the second quarter with $153.2 million in cash and cash equivalents. Its balance sheet is currently strong enough to support growth without excessive dilution. Various factors, including aging demographics, a shift toward minimally invasive surgical methods, digitization, robotics, and surgeons demanding better tools, could drive the spine surgery market forward. Alphatec has established a strong moat by combining software, hardware, and biologics into a streamlined ecosystem focused solely on spine surgery solutions. Its rapid revenue growth, improving margins, and expanding moat indicate that the company is on track to profitability. CEO Pat Miles believes, 'We are built to lead, and the best is yet to come.' The company will release its second-quarter earnings on July 31. Analysts expect revenue to rise 22.5% to $178.8 million. For the full year, analysts project revenue growth of 20%, which is consistent with management's projections, with an additional 18.3% increase in 2026. Alphatec, trading at 2x forward sales, is a reasonable buy for a company with significant growth potential in the spine surgery market. Is Alphatec Stock a Buy, Hold, or Sell? The consensus on Alphatec stock is a "Strong Buy.' Of the 11 analysts covering ATEC, nine have rated it a 'Strong Buy,' one recommends a 'Moderate Buy,' and one says it is a 'Hold.' Based on its mean price target of $18.32, Wall Street expects the stock to climb as high as 74% from current levels. Furthermore, its Street-high estimate of $22.50 implies potential upside of nearly 113.6% in the next 12 months. The Bottom Line on ATEC Stock The global spine surgery market is massive, valued at more than $14.5 billion and expected to reach $19.1 billion by 2030. Alphatec is a small player in the medtech industry, but its focus on spine surgery solutions gives it a competitive advantage. Given this advantage, it is ahead of the competition. Alphatec, like most small-cap biotech growth stocks, is highly volatile. However, it remains an excellent choice for those seeking exposure to medical innovation with genuine long-term upside and who are willing to bear the short-term risks. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
17-07-2025
- Business
- Yahoo
ATEC to Report Second Quarter 2025 Financial Results on July 31, 2025
CARLSBAD, Calif., July 17, 2025--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report second quarter 2025 financial results on July 31, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-In To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Inducement Awards Granted As an inducement material to accepting employment with the Company, and in accordance with Nasdaq Listing Rule 5635(c)(4), ATEC today announced that the independent Compensation Committee of the Board of Directors has approved aggregate grants to 37 new employees (who are not executive officers) of, collectively, 61,096 restricted stock units ("RSUs") under the Company's 2016 Employment Inducement Award Plan. The RSUs will vest in equal annual installments on each of the first four anniversaries of the grant date, provided that the recipient remains continuously employed by ATEC as of such vesting date. In addition, the RSUs will vest fully upon a change of control of ATEC. View source version on Contacts Investor/Media Contact: Robert JuddInvestor Relations(760) 494-6790investorrelations@ Company Contact: J. Todd KoningChief Financial Officerinvestorrelations@ Sign in to access your portfolio
Business Wire
17-07-2025
- Business
- Business Wire
ATEC to Report Second Quarter 2025 Financial Results on July 31, 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report second quarter 2025 financial results on July 31, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-In To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Inducement Awards Granted As an inducement material to accepting employment with the Company, and in accordance with Nasdaq Listing Rule 5635(c)(4), ATEC today announced that the independent Compensation Committee of the Board of Directors has approved aggregate grants to 37 new employees (who are not executive officers) of, collectively, 61,096 restricted stock units ('RSUs') under the Company's 2016 Employment Inducement Award Plan. The RSUs will vest in equal annual installments on each of the first four anniversaries of the grant date, provided that the recipient remains continuously employed by ATEC as of such vesting date. In addition, the RSUs will vest fully upon a change of control of ATEC.
Yahoo
19-06-2025
- Business
- Yahoo
Why This Beaten Down Biotech Stock Might Be a Hidden Gem
In the volatile biotech industry, it is easy to overlook small-cap medical device companies, particularly those that are not yet profitable. But every now and then, a company slips under the radar despite having the ideal combination of innovation, market opportunity, and long-term strategic execution. One such company is Alphatec Holdings (ATEC), a medical technology firm specializing in advanced spine surgery solutions. Alphatec uses artificial intelligence (AI) technologies to improve surgical precision, automate signal monitoring, and provide intraoperative analytics. While it is not a pure-play AI company, AI is becoming more integrated into its platform, helping to shape the future of spine surgery. Dear Tesla Stock Fans, Mark Your Calendars for June 22 Nvidia Says Quantum Computing Is Nearing an 'Inflection Point.' Here Are the 3 Best Stocks to Buy Now to Profit. Warren Buffett Loves This Cheap Dividend Stock and So Do Company Insiders Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. With consistent revenue growth, ATEC is gradually gaining traction. Valued at a market capitalization of $1.6 billion, Alphatec stock has risen 21% year to date (YTD), outperforming the S&P 500 Index's ($SPX) gain of 2.2% YTD. Long-term investors who are willing to dig deeper may find this beaten-down growth stock to be a hidden gem. Founded in 1990, Alphatec initially focused on spinal implants and surgical instrumentation. However, it is now reimagining spine surgery as a fully integrated experience, with cutting-edge implants, navigation systems, and surgical software. The company's platform is intended to assist spine surgeons in operating with greater precision, reducing complications, shortening patient recovery times, and collecting intraoperative data for better long-term outcomes. Alphatec has achieved double-digit revenue growth lately, owing to increased surgeon adoption and new product launches. In the first quarter of 2025, total revenue increased 22% year on year to $169 million, with surgical revenue up 24%. Procedure volume is increasing as more surgeons use Alphatec's approaches. The company is quickly becoming a preferred partner for spine surgeons because of its technological capabilities. In Q1, Alphatec experienced an 18% increase in new surgeon adoption. Like most growth companies, Alphatec has yet to turn a profit despite increasing revenues. These losses are largely the result of aggressive reinvestment in growth, research and development (R&D), and surgeon support. During the quarter, the company spent $16.58 million on R&D. Adjusted gross margin reached 70.4% in the quarter. Looking at the firm's consistent revenue growth and margins, profitability may not be far away, especially if the company continues to increase procedure volumes and expand its ecosystem. Adjusted EBITDA stood at $10.5 million in the quarter, up from a $3 million loss in the year-ago quarter. At the end of Q1, Alphatec had $153.2 million in cash and cash equivalents. Management expects adjusted EBITDA of $78 million in 2025, compared to $31 million in the previous year. Analysts covering Alphatec predict that revenue will increase by 20.1% in 2025, in line with management's expectations. Revenue could rise by 18.3% in 2026, with losses gradually declining. The U.S. spine surgery market is large and growing, with a projected value of $20 billion by 2031. Chronic back pain and spinal deformities are on the rise, owing to the aging population and climbing obesity rates. While Alphatec's market share remains small, this allows the company plenty of room to grow. As demand for more precise and less invasive surgeries increases, the few companies like Alphatec with integrated, AI-capable surgical platforms may lead their industry. Of course, growing biotech stocks can be risky. Alphatec faces stiff competition from larger, established players in the medical technology industry, such as Intuitive Surgical (ISRG), Stryker (SYK), and Medtronic (MDT). Furthermore, continued losses may necessitate additional capital raises or risk share dilution. For a company in its early growth stages, however, these risks are manageable, especially given Alphatec's strong traction with both products and customers. Its sole focus on spine surgery also distinguishes the firm as an expert in its field, which is also known as a moat. Still, because Alphatec is a growing biotech company, ATEC is better suited for aggressive investors willing to hold the stock until it reaches its full potential. Last month, H.C. Wainwright analyst Sean Lee reiterated his 'Buy' rating on ATEC stock, citing the company's strong Q1 2025 performance and growth trajectory. Lee emphasized Alphatec's improved profitability, citing consecutive quarters of positive adjusted EBITDA and a decrease in cash burn. The company now expects positive cash flow by year-end, with a projected increase in adjusted EBITDA for 2025. Despite regulatory and financial risks, Lee believes Alphatec is well-positioned for long-term growth. Backed by valuation metrics like EV-to-sales and DCF analysis, Lee set a 12-month price target of $20 per share. Separately, Barclays also maintained a 'Buy' rating on ATEC with a price target of $21. Recently, Lake Street initiated coverage of ATEC stock with a price target of $18 and a 'Buy' rating. According to the analyst, Alphatec is the only major spine company fully committed to improving spinal surgery outcomes, while the rest of the industry appears disorganized or uncertain. Lake Street also predicts that Alphatec's exceptional growth rate will continue. On Wall Street, ATEC is rated a 'Strong Buy' by consensus. Of the 11 analysts covering the stock, nine have rated it a 'Strong Buy' while one analyst recommends a 'Moderate Buy' rating and one rates the stock a 'Hold.' Based on its mean price target of $18.32, Wall Street expects the stock to climb as high as 66% from current levels. Furthermore, the Street-high estimate of $22.50 per share implies potential upside of nearly 105% over the next 12 months. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-06-2025
- Business
- Yahoo
Lake Street Capital Initiates Buy on Alphatec Holdings, Inc. (ATEC) with 63% Upside
Alphatec Holdings, Inc. (NASDAQ:ATEC) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at Lake Street Capital Markets initiated a high-note coverage on Aphatec Holdings with a Buy rating and price target of $18, implying a solid jump of 63% from its current trading price of $11.02. What's driving the optimistic outlook? As Lake Street highlights, 'Alphatec Holdings, Inc. (NASDAQ:ATEC) represents the only scaled spine player totally focused on improving spine outcomes while much of the industry borders on totally confused.' A medical professional guiding a robotic tool placing pedicle screws in a patient's spinal column. This positive coverage followed a non-deal roadshow in New York City, where Alphatec's management and Lake Street analysts met to discuss the company's goals and strategic plans. The investment bank believes that the company will continue to surpass growth rates driven by a focus on a niche spine treatments market. This is reinforced by the 20.04% year-to-date return delivered by the giant in contrast to the return of merely 2.58% by the broader market. Alphatec Holdings, Inc. (NASDAQ:ATEC) is a California-based medical technology company that engages in the design and advancement of surgical treatment of spinal disorders technologies. Founded in 1990, the core offerings of the company include the Alpha InformatiX product platform, VEA alignment mobile application, and PTP Patient Positioning Systems. The company aims to become 'The Standard-Bearer in Spine.' While we acknowledge the potential of ATEC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
